Dynavax Technologies (LTS:0IDA) COGS-to-Revenue : 0.22 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Dynavax Technologies COGS-to-Revenue?

Dynavax Technologies's Cost of Goods Sold for the three months ended in Mar. 2024 was $11.0 Mil. Its Revenue for the three months ended in Mar. 2024 was $50.8 Mil.

Dynavax Technologies's COGS to Revenue for the three months ended in Mar. 2024 was 0.22.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Dynavax Technologies's Gross Margin % for the three months ended in Mar. 2024 was 78.41%.

Dynavax Technologies COGS-to-Revenue Historical Data

The historical data trend for Dynavax Technologies's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dynavax Technologies COGS-to-Revenue Chart

Dynavax Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.55

0.30

0.39

0.36

0.22

Dynavax Technologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.31	0.22	0.19	0.16	0.22

Dynavax Technologies COGS-to-Revenue Calculation

Dynavax Technologies's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	50.167	/	232.284
	=	0.22

Dynavax Technologies's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	10.966	/	50.79
	=	0.22

Dynavax Technologies (LTS:0IDA) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Dynavax Technologies's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	10.966 / 50.79
	=	78.41 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Dynavax Technologies COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Dynavax Technologies's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Dynavax Technologies (LTS:0IDA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dynavax Technologies Corp (LTS:0IDA) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

DVAX:USA DYF1:Germany

Address

2100 Powell Street, Suite 900, Emeryville, CA, USA, 94608

Website

https://www.dynavax.com

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Dynavax Technologies (LTS:0IDA) Headlines

No Headlines